Background: Hyaluronic acid (HA) fillers are the most popular filler agents for skin rejuvenation. Although 1,4-butanediol diglycidyl ether is regarded as a relatively safe cross-linker, it still exhibits certain cytotoxicity. Objectives: We presented here an amino acid–cross-linked HA (ACHA) which was obtained by an amidation reaction with lysine and HA. This study aimed to investigate ACHA's efficacy and safety for skin augmentation and rejuvenation. Methods: Rheology, compressive tests, and swelling experiments were conducted to investigate ACHA's mechanical and viscoelastic properties. The effects of ACHA on the human keratinocytes (HaCaT) cells and the human dermal fibroblast (HDF) were investigated by Transwell and wound healing assays. Its impacts on the epithelial thickness and collagen synthesis were further examined in a mouse experimental model. We recruited 50 patients with moderate to severe nasolabial folds (NLFs). The patients were randomly allocated to receive ACHA or Restylane injections. The resulting retention rates of HA and the Wrinkle Severity Rating Scale and Global Aesthetic Improvement Scale outcomes were evaluated and compared. Results: ACHA exhibited good viscoelasticity. It not only promoted migration and proliferation of HaCat and HDF and secretion of various growth factors but also increased skin thickness and promoted the generation of collagen. Patients who received ACHA had more residual volume 12 months after treatment. ACHA exhibited a promising augmentation effect in NLF correction with few adverse reactions. Conclusions: ACHA has shown promise as a biomaterial with excellent biocompatibility and viscoelastic characteristics in both research and the clinic. See the abstract translated into Hindi, Portuguese, Korean, German, Italian, Arabic, Chinese, and Taiwanese online here: https://doi.org/10.1093/asj/sjad169. Level of Evidence: 2:
Hyaluronic acid (HA) has already been widely used for chin augmentation. Patients with chin retrusion frequently present with increased chin hypertonia. Monotherapy with HA falls short in addressing the multifaceted cosmetic concerns associated with chin retrusion. This study aimed to investigate the clinical efficacy and safety of the combination therapy involving Botulinum Toxin (BTX) and HA in the treatment of chin retrusion. We enrolled subjects with moderate to severe chin retrusion for a 9-month follow-up, where they received either combined treatment with BTX plus HA or monotreatment with HA. We also calculated surface-volume coefficient using 3D digital scanning technique, and evaluated outcomes based on Allergan Chin Retrusion Scale (ACRS), Global Aesthetic Improvement Scale (GAIS) and Treatment-Related Adverse Events (TRAEs). A total of 50 subjects were recruited and randomized in treatment group (BTX plus HA) or control group (HA alone) in a 1:1 ratio. Subjects in treatment group exhibited significantly higher surface-volume coefficients during the first 6 months (p < 0.05). ACRS scores and responder rates in two groups remained similar throughout the follow-up (p > 0.05). Within the initial 3 months, the GAIS responder rate in treatment group was significantly higher than that in control group (p < 0.05). Mild TRAEs were observed in both groups, and subsided within 7 days. There was no increase in adverse effects with the combined treatment. In comparison to monotherapy, the combined treatment not only improved the surface-volume coefficient of Hyaluronic acid but also achieved similar ACRS scores using less HA volume. Furthermore, it yielded superior treatment outcomes for individuals with chin retrusion.
With the development of society and the economy, the incidence of diabetic foot ulcers continues to increase. Currently, conventional debridement with dressing changes, hyperbaric oxygen, and vacuum sealing drainage are the main conservative treatments in clinical practice, and large wounds often require skin grafts or skin flap grafts. However, the treatment effects are not ideal, and many complications exist. Due to its complex pathogenesis, long treatment time, significant associated difficulties, and high disability rate, diabetic foot ulcers cause a heavy burden to patients, society, and medical care. According to our previous study, the pharmacological effects of human umbilical cord blood stem cells include nonspecific immune regulation; increased secretion of growth factors, vasoactive factors, and anti-inflammatory factors; enhanced anti-infectious ability of the human body; elimination of inflammation; and promotion of angiogenesis and ulcer healing. These effects suggest stem cells may be useful as an autologous or allogeneic treatment for refractory wounds. Therefore, we are conducting a clinical trial to treat refractory diabetic wounds with human umbilical cord stem cells in our clinic for diabetic foot ulcer patients who meet the inclusion criteria.
Skin trauma, particularly chronic non-healing wounds, imposes significant economic and physical burdens on patients and their families. A defining feature of these wounds is persistent dysregulated inflammation, with macrophage efferocytosis playing a critical role. Efferocytosis-the programmed removal of apoptotic cells (ACs) by macrophages-is vital for resolving inflammation and facilitating tissue repair. In chronic wounds associated with systemic diseases such as diabetes, impaired macrophage efferocytosis hinders AC clearance, leading to prolonged inflammation and delayed healing. This review focuses on the molecular mechanisms regulating macrophage efferocytosis during inflammation and discusses clinical strategies to improve the healing of chronic wounds.
Metabolic memory (MM) is a major factor in the delayed wound healing observed in diabetic patients. While “Nocardia rubrum cell wall skeleton” (Nr-CWS) is utilized to enhance macrophage proliferation in immune diseases, its impact on MM wounds in diabetes is unclear. This study demonstrates that transient hyperglycemia leads to prolonged damage in vascular endothelial cells by decreasing METTL3 expression, leading to decreased RNA methylation and impaired cellular metabolism. Remarkably, Nr-CWS application increases METTL3 levels in these cells, facilitating the recovery of cell function. Further in vivo and in vitro analyses demonstrate that transient hyperglycemia-induced reduction in METTL3 hinders RNA methylation of the downstream gene Cds2, impacting mitochondrial function and energy metabolism and consequently reducing angiogenic capacity in endothelial cells. This impairment significantly influences diabetic wound healing. Our findings highlight the profound impact of transient hyperglycemia on wound healing, establishing METTL3 as a significant role in vascular complications of diabetes. This study not only elucidates the pathophysiological mechanisms behind MM in diabetic wounds but also suggests Nr-CWS as a potential therapeutic agent, offering a novel approach for treating diabetic wounds.